[go: up one dir, main page]

CL2013003160A1 - Compounds derived from 4h-chromen-4-one modulators of the protein kinase pi3k; intermediary compounds; pharmaceutical composition that includes them; and useful in the treatment of cancer, anti-inflammatory agents, immunosuppressants, steroids, analgesics, leukemia, among others. - Google Patents

Compounds derived from 4h-chromen-4-one modulators of the protein kinase pi3k; intermediary compounds; pharmaceutical composition that includes them; and useful in the treatment of cancer, anti-inflammatory agents, immunosuppressants, steroids, analgesics, leukemia, among others.

Info

Publication number
CL2013003160A1
CL2013003160A1 CL2013003160A CL2013003160A CL2013003160A1 CL 2013003160 A1 CL2013003160 A1 CL 2013003160A1 CL 2013003160 A CL2013003160 A CL 2013003160A CL 2013003160 A CL2013003160 A CL 2013003160A CL 2013003160 A1 CL2013003160 A1 CL 2013003160A1
Authority
CL
Chile
Prior art keywords
compounds
chromen
immunosuppressants
analgesics
steroids
Prior art date
Application number
CL2013003160A
Other languages
Spanish (es)
Inventor
Dhanapalan Nagarathnam
Prashant Kashinath Bhavar
Swaroop Kumar Vakkalanka
Meyyappan Muthuppalaniappan
Srikant Viswanadha
Govindarajula Babu
Original Assignee
Rhizen Pharmaceuticals S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46147717&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2013003160(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rhizen Pharmaceuticals S A filed Critical Rhizen Pharmaceuticals S A
Publication of CL2013003160A1 publication Critical patent/CL2013003160A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/34—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only
    • C07D311/36—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only not hydrogenated in the hetero ring, e.g. isoflavones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Otolaryngology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)

Abstract

La presente invención proporciona compuestos derivados de 4H-cromen-4-ona moduladores de la proteína cinasa PI3K, de formula I; compuestos intermediarios; composición farmacéutica que los comprende; y útiles en el tratamiento del cáncer, agentes antinflamatorios, inmunosupresores, esteroides, analgésicos, leucemia, entre otros.The present invention provides compounds derived from 4H-chromen-4-one modulators of the PI3K protein kinase, of formula I; intermediary compounds; pharmaceutical composition comprising them; and useful in the treatment of cancer, anti-inflammatory agents, immunosuppressants, steroids, analgesics, leukemia, among others.

CL2013003160A 2011-05-04 2013-11-04 Compounds derived from 4h-chromen-4-one modulators of the protein kinase pi3k; intermediary compounds; pharmaceutical composition that includes them; and useful in the treatment of cancer, anti-inflammatory agents, immunosuppressants, steroids, analgesics, leukemia, among others. CL2013003160A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1542CH2011 2011-05-04
IN81CH2012 2012-01-09

Publications (1)

Publication Number Publication Date
CL2013003160A1 true CL2013003160A1 (en) 2014-09-26

Family

ID=46147717

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2013003160A CL2013003160A1 (en) 2011-05-04 2013-11-04 Compounds derived from 4h-chromen-4-one modulators of the protein kinase pi3k; intermediary compounds; pharmaceutical composition that includes them; and useful in the treatment of cancer, anti-inflammatory agents, immunosuppressants, steroids, analgesics, leukemia, among others.

Country Status (29)

Country Link
US (5) US9775841B2 (en)
EP (1) EP2705029B1 (en)
JP (2) JP6118314B2 (en)
KR (1) KR101992311B1 (en)
CN (2) CN103702989B (en)
AP (1) AP4075A (en)
AU (1) AU2012250576B2 (en)
BR (1) BR112013027774B1 (en)
CA (1) CA2833935C (en)
CL (1) CL2013003160A1 (en)
CO (1) CO6852069A2 (en)
CY (1) CY1121170T1 (en)
DK (1) DK2705029T3 (en)
EA (1) EA024842B9 (en)
ES (1) ES2710874T3 (en)
HR (1) HRP20190128T1 (en)
HU (1) HUE042322T2 (en)
LT (1) LT2705029T (en)
MX (1) MX365160B (en)
MY (1) MY168757A (en)
PH (1) PH12013502240B1 (en)
PL (1) PL2705029T4 (en)
PT (1) PT2705029T (en)
RS (1) RS58326B1 (en)
SG (1) SG194718A1 (en)
SI (1) SI2705029T1 (en)
SM (1) SMT201900056T1 (en)
WO (1) WO2012151525A1 (en)
ZA (1) ZA201307964B (en)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20171537T1 (en) 2009-11-05 2017-12-15 Rhizen Pharmaceuticals S.A. Novel benzopyran kinase modulators
BR112013027774B1 (en) 2011-05-04 2020-11-17 Rhizen Pharmaceuticals S.A. pharmaceutical compound and composition
US9914722B2 (en) 2012-03-23 2018-03-13 Ptc Therapeutics, Inc. Compounds for treating spinal muscular atrophy
US10130635B2 (en) 2012-05-04 2018-11-20 Rhizen Pharmaceuticals Sa Process for preparation of optically pure and optionally substituted 2-(1-hydroxy-alkyl)-chromen-4-one derivatives and their use in preparing pharmaceuticals
CN108084138A (en) 2012-05-04 2018-05-29 理森制药股份公司 Prepare the method and its pharmaceutical applications of optical voidness 2- (1- hydroxyl-alkyls)-chromen-4-one derivatives
ES2647416T3 (en) * 2012-07-04 2017-12-21 Rhizen Pharmaceuticals S.A. Selective delta PI3K inhibitors
KR20150079745A (en) 2012-11-08 2015-07-08 리젠 파마슈티컬스 소시에떼 아노님 Pharmaceutical compositions containing a pde4 inhibitor and a pi3 delta or dual pi3 delta-gamma kinase inhibitor
AP2015008888A0 (en) 2013-06-07 2015-11-30 Rhizen Pharmaceuticals Sa Dual selective pi3 delta and gamma kinase inhibitors
CN111153905A (en) 2013-07-02 2020-05-15 理森制药股份公司 PI3K protein kinase inhibitors, in particular delta inhibitors and/or gamma inhibitors
TWI672297B (en) * 2013-12-18 2019-09-21 義大利商吉斯藥品公司 Isochromene derivatives as phosphoinositide 3-kinases inhibitors
PH12016502572B1 (en) 2014-06-27 2022-05-04 Rhizen Pharmaceuticals Sa Substituted chromene derivatives as selective dual inhibitors of pi3 delta and gamma protein kinases
WO2016011394A1 (en) * 2014-07-18 2016-01-21 The General Hospital Corporation Imaging agents for neural flux
DK3188759T3 (en) * 2014-09-03 2020-06-29 Rhizen Pharmaceuticals S A METHOD OF TREATMENT AND COMPOSITIONS CONTAINING A DOUBLE PI3K-DELTA-GAMMA KINASE INHIBITOR AND A CORTIC COSTEROID
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
CN104610331A (en) * 2015-02-26 2015-05-13 成都安斯利生物医药有限公司 Method for preparing 4-(1,3-oxazine-2-yl)phenylboronic acid
CN105936635B (en) * 2015-03-06 2019-06-21 南京圣和药业股份有限公司 Compound and its application as phosphatidyl-inositol 3-kinase delta inhibitor
CN106008479B (en) * 2015-03-06 2020-01-10 南京圣和药业股份有限公司 Substituted pyrimidine compound as phosphatidylinositol 3-kinase delta inhibitor and application thereof
US9968604B2 (en) * 2015-04-16 2018-05-15 Chiesi Farmaceutici S.P.A. Chromene derivatives as phoshoinositide 3-kinases inhibitors
CN108137514A (en) * 2015-07-30 2018-06-08 百时美施贵宝公司 aryl-substituted bicyclic heteroaryl compounds
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
KR102447711B1 (en) * 2016-06-20 2022-09-28 시오노기세야쿠 가부시키가이샤 Method for preparing substituted polycyclic pyridone derivatives and crystals thereof
CN106831636A (en) * 2016-12-12 2017-06-13 湖南华腾制药有限公司 A kind of preparation method of oxadiazole compound
DK3606926T3 (en) * 2017-04-05 2021-07-05 Curovir Ab HETEROAROMATIC COMPOUNDS USE IN THERAPY
CN107652261B (en) * 2017-09-30 2020-08-07 桂林医学院 A kind of isoflavone derivative and synthesis method thereof
WO2019143874A1 (en) 2018-01-20 2019-07-25 Sunshine Lake Pharma Co., Ltd. Substituted aminopyrimidine compounds and methods of use
GB2578417B (en) * 2018-06-11 2022-09-28 Hunt Dev Uk Ltd Airway sampling device and associated methods
TW202128699A (en) * 2019-11-27 2021-08-01 美商建南德克公司 Therapeutic compounds
KR20210099402A (en) * 2020-02-04 2021-08-12 고려대학교 산학협력단 Pharmaceutical composition for preventing or treating diseases related to abnormal proliferation of endometrial cells or trophoblast cells comprising fenbendazole, oxibendazole or mixture thereof
JP7624240B2 (en) * 2020-05-11 2025-01-30 タレンゲン インターナショナル リミテッド Methods and drugs for treating spinal muscular atrophy
ES3037417T3 (en) 2020-05-14 2025-10-01 Rhizen Pharmaceuticals Ag Purine derivatives as sik-3 inhibitors
US20240360154A1 (en) * 2020-09-23 2024-10-31 Genfleet Therapeutics (Shanghai) Inc. Aroyl substituted tricyclic compound, preparation method therefor and use thereof
CN116410195B (en) * 2021-12-31 2025-07-18 同润生物医药(上海)有限公司 A kind of adipate crystal and preparation method thereof
CN116410193A (en) * 2021-12-31 2023-07-11 同润生物医药(上海)有限公司 Hemi-fumarate crystal of PI3Kδ/γ dual inhibitor compound and preparation method thereof
CN116410194B (en) * 2021-12-31 2025-07-18 同润生物医药(上海)有限公司 A benzenesulfonate crystal and preparation method thereof
TW202328132A (en) * 2021-12-31 2023-07-16 大陸商同潤生物醫藥(上海)有限公司 HEMI-FUMARATE CRYSTALS OF PI3Kδ/γ DUAL INHIBITOR COMPOUND AND PREPARATION METHOD THEREOF
CN114891005B (en) * 2022-03-30 2024-01-19 武汉九州钰民医药科技有限公司 Preparation process of Wupalision p-toluenesulfonate
KR102616744B1 (en) * 2023-04-10 2023-12-27 한국교통대학교산학협력단 Composition for healthy intestine comprising fermented grapefruit extract
WO2025072438A1 (en) * 2023-09-27 2025-04-03 Bristol-Myers Squibb Company Piperidine substituted pyrazolopyrimidine derivatives as inhibitors of sgk1

Family Cites Families (126)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3691016A (en) 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
CA1023287A (en) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
FR2224144B1 (en) 1973-04-06 1976-04-09 Rech Pharmaceutiq Scientif
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
US4289872A (en) 1979-04-06 1981-09-15 Allied Corporation Macromolecular highly branched homogeneous compound based on lysine units
JPS6023084B2 (en) 1979-07-11 1985-06-05 味の素株式会社 blood substitute
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DE3675588D1 (en) 1985-06-19 1990-12-20 Ajinomoto Kk HAEMOGLOBIN TIED TO A POLY (ALKENYLENE OXIDE).
JPS62201882A (en) 1985-11-18 1987-09-05 Yamanouchi Pharmaceut Co Ltd Isoflavon derivative
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4925673A (en) 1986-08-18 1990-05-15 Clinical Technologies Associates, Inc. Delivery systems for pharmacological agents encapsulated with proteinoids
US5229490A (en) 1987-05-06 1993-07-20 The Rockefeller University Multiple antigen peptide system
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
JPH07505915A (en) 1992-04-14 1995-06-29 コーネル　リサーチ　ファウンデーション、インコーポレーテッド Dendritic macromolecules and their production method
US5646176A (en) 1992-12-24 1997-07-08 Bristol-Myers Squibb Company Phosphonooxymethyl ethers of taxane derivatives
US5455258A (en) 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
JPH08175990A (en) 1994-12-19 1996-07-09 Mitsubishi Chem Corp PI3 kinase inhibitor and method for producing the same
JPH08176070A (en) 1994-12-19 1996-07-09 Mitsubishi Chem Corp Didepside derivative and PI3 kinase inhibitor
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
JP3053222B2 (en) 1995-04-20 2000-06-19 ファイザー・インコーポレーテッド Arylsulfonylhydroxamic acid derivatives as MMP and TNF inhibitors
GB9521987D0 (en) 1995-10-26 1996-01-03 Ludwig Inst Cancer Res Phosphoinositide 3-kinase modulators
PT780386E (en) 1995-12-20 2003-02-28 Hoffmann La Roche MATRIX METALOPROTEASE INHIBITORS
AU712973B2 (en) 1996-07-18 1999-11-18 Pfizer Inc. Phosphinate based inhibitors of matrix metalloproteases
AU711585B2 (en) 1996-08-23 1999-10-14 Pfizer Inc. Arylsulfonylamino hydroxamic acid derivatives
AU5131998A (en) 1997-01-06 1998-08-03 Pfizer Inc. Cyclic sulfone derivatives
PL335027A1 (en) 1997-02-03 2000-03-27 Pfizer Prod Inc Derivatives of arylsulphonylamino hydroxamic acid
BR9807824A (en) 1997-02-07 2000-03-08 Pfizer Derivatives of n-hydroxy-beta-sulfonyl-propionamide and its use as matrix metalloproteinase inhibitors
JP3710489B2 (en) 1997-02-11 2005-10-26 ファイザー・インク Arylsulfonylhydroxamic acid derivatives
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
GB9725782D0 (en) 1997-12-05 1998-02-04 Pfizer Ltd Therapeutic agents
GB9801690D0 (en) 1998-01-27 1998-03-25 Pfizer Ltd Therapeutic agents
PA8469401A1 (en) 1998-04-10 2000-05-24 Pfizer Prod Inc BICYCLE DERIVATIVES OF HYDROXAMIC ACID
PA8469501A1 (en) 1998-04-10 2000-09-29 Pfizer Prod Inc HYDROXAMIDES OF THE ACID (4-ARILSULFONILAMINO) -TETRAHIDROPIRAN-4-CARBOXILICO
KR100685336B1 (en) 1999-02-22 2007-02-23 게젤샤프트 퓌어 비오테크놀로기쉐 포르슝 엠베하(게베에프) C-21 modified epothilone
JP2001247477A (en) 2000-03-03 2001-09-11 Teikoku Hormone Mfg Co Ltd Antitumor agent
SI3029041T1 (en) 2000-04-25 2020-08-31 Icos Corporation Inhibitors of human phosphatidyl-inositol 3-kinase delta
US6608053B2 (en) 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
US6403588B1 (en) 2000-04-27 2002-06-11 Yamanouchi Pharmaceutical Co., Ltd. Imidazopyridine derivatives
ES2236481T3 (en) 2001-01-16 2005-07-16 Glaxo Group Limited PHARMACEUTICAL COMBINATION CONTAINING A 4-QUINAZOLINAMINE AND PACLITAXEL, CARBOPLATIN OR VINORELBINE FOR CANCER TREATMENT.
CA2454976C (en) 2001-07-26 2011-05-10 Santen Pharmaceutical Co., Ltd. Therapeutic agent for glaucoma comprising compound having pi3 kinase inhibitory action as active ingredient
US6703414B2 (en) 2001-09-14 2004-03-09 Arizona Board Of Regents On Behalf Of The University Of Arizona Device and method for treating restenosis
AU2002357667A1 (en) 2001-10-24 2003-05-06 Iconix Pharmaceuticals, Inc. Modulators of phosphoinositide 3-kinase
US6908932B2 (en) 2001-10-24 2005-06-21 Iconix Pharmaceuticals, Inc. Modulators of phosphoinositide 3-kinase
EP1444010A2 (en) 2001-10-30 2004-08-11 Pharmacia Corporation Heteroaromatic carboxamide derivatives for the treatment of inflammation
DK1511734T3 (en) * 2002-04-17 2010-08-02 Cytokinetics Inc Compounds, Preparations and Methods
EA011807B1 (en) 2002-07-10 2009-06-30 Лаборатуар Сероно Са Azolidinone-vinyl fused-benzene derivatives
JP2006500327A (en) 2002-07-10 2006-01-05 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ Use of compounds to increase sperm motility
US20040092561A1 (en) 2002-11-07 2004-05-13 Thomas Ruckle Azolidinone-vinyl fused -benzene derivatives
AU2003255845A1 (en) 2002-08-22 2004-03-11 Piramed Limited Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents
US7601724B2 (en) 2002-09-04 2009-10-13 Schering Corporation Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
US7605155B2 (en) 2002-09-04 2009-10-20 Schering Corporation Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
DE10256174A1 (en) 2002-12-02 2004-06-09 Merck Patent Gmbh 2-Benzoylchromonderivate
WO2004072029A2 (en) 2003-02-06 2004-08-26 Vertex Pharmaceuticals Incorporated Pyrazolopyridazines useful as inhibitors of protein kinases
GB0305152D0 (en) * 2003-03-06 2003-04-09 Novartis Ag Organic compounds
DE602004023838D1 (en) 2003-04-24 2009-12-10 Merck & Co Inc HEMMER OF ACT ACTIVITY
WO2005013982A1 (en) 2003-08-06 2005-02-17 Vertex Pharmaceuticals Incorporated Aminotriazole compounds useful as inhibitors of protein kinases
US7501427B2 (en) 2003-08-14 2009-03-10 Array Biopharma, Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
US20050043239A1 (en) 2003-08-14 2005-02-24 Jason Douangpanya Methods of inhibiting immune responses stimulated by an endogenous factor
MXPA06006651A (en) * 2003-12-09 2006-08-11 Gov Health & Human Serv Methods for suppressing an immune response or a treating a proliferative disorder.
WO2005113556A1 (en) * 2004-05-13 2005-12-01 Icos Corporation Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
CN101065016A (en) 2004-09-24 2007-10-31 詹森药业有限公司 Imidazo{4,5-b}pyrazinone inhibitors of protein kinases
GB0423653D0 (en) 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
WO2008007113A2 (en) 2006-07-14 2008-01-17 Astex Therapeutics Limited Pharmaceutical combinations
FR2882751B1 (en) 2005-03-04 2007-09-14 Aventis Pharma Sa HYDRAZINOCARBONYL-THIENO [2,3-C] PYRAZOLES, PROCESS FOR THEIR PREPARATION, COMPOSITIONS CONTAINING SAME AND USE THEREOF
EP1904449A4 (en) 2005-07-08 2010-07-28 Merck Sharp & Dohme INHIBITORS OF KINASES "POINTS OF CONTROL"
MX2008002165A (en) 2005-08-16 2008-04-29 Irm Llc Compounds and compositions as protein kinase inhibitors.
CA2621879A1 (en) 2005-09-06 2007-03-15 Smithkline Beecham Corporation Benzimidazole thiophene compounds as plk inhibitors
HRP20130902T1 (en) 2005-10-07 2013-11-08 Exelixis Inc. PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kalpha
GB0520657D0 (en) 2005-10-11 2005-11-16 Ludwig Inst Cancer Res Pharmaceutical compounds
JP2009512706A (en) 2005-10-21 2009-03-26 メルク エンド カムパニー インコーポレーテッド Tyrosine kinase inhibitor
CN101421265A (en) 2006-01-18 2009-04-29 安姆根有限公司 Thiazole compounds as protein kinase b (pkb) inhibitors
WO2007099317A1 (en) 2006-03-02 2007-09-07 Astrazeneca Ab Quinazoline derivatives
WO2007126841A2 (en) 2006-03-29 2007-11-08 Foldrx Pharmaceuticals, Inc. Inhibition of alpha-synuclein toxicity
WO2007117995A2 (en) 2006-03-30 2007-10-18 Takeda San Diego, Inc. Kinase inhibitors
GB2453058A (en) * 2006-04-04 2009-03-25 Univ California Kinase antagonists
NZ572812A (en) 2006-04-26 2010-09-30 Hoffmann La Roche THIENO [3, 2-D] PYRIMIDINE Indazole DERIVATIVE USEFUL AS PI3K INHIBITOR
EP2046799B1 (en) 2006-04-26 2017-07-19 Genentech, Inc. Phosphoinositide 3-kinase inhibitor compounds and pharmaceutical compositions containing them
CA2652328A1 (en) 2006-05-15 2007-11-22 Takeda Pharmaceutical Company Limited Prophylactic and therapeutic agent for cancer
GB0610243D0 (en) 2006-05-23 2006-07-05 Novartis Ag Organic compounds
ES2393410T3 (en) 2006-08-09 2012-12-21 Bristol-Myers Squibb Company Kinase inhibitor pyrrolotriazines
EP2064203A1 (en) 2006-09-14 2009-06-03 AstraZeneca AB 2-benzimidaz0lyl-6-m0rph0lin0-4-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
SG178786A1 (en) 2006-11-13 2012-03-29 Lilly Co Eli Thienopyrimidinones for treatment of inflammatory disorders and cancers
JP5284977B2 (en) 2006-12-07 2013-09-11 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Phosphoinositide 3-kinase inhibitor compounds and methods of use
WO2008073785A2 (en) 2006-12-07 2008-06-19 Genentech, Inc. Phosphoinositide 3-kinase inhibitor compounds and methods of use
AU2008231384B2 (en) 2007-03-23 2011-09-15 Amgen Inc. Heterocyclic compounds and their use
US7592342B2 (en) 2007-05-10 2009-09-22 Smithkline Beecham Corporation Quinoxaline derivatives as PI3 kinase inhibitors
US20090263397A1 (en) 2007-07-06 2009-10-22 Buck Elizabeth A Combination anti-cancer therapy
CN104926815B (en) * 2008-01-04 2017-11-03 英特利凯恩有限责任公司 Some chemical entities, composition and method
CL2009000400A1 (en) 2008-02-22 2010-09-10 Irm Llc Heterocyclic compounds derived from 3-phenyl-1,6-naphthyridin-2-one; modulators of kinase activity; pharmaceutical composition; and use in the treatment of diseases such as allergic disorders, autoimmune disorders, neoplasms, rejection in organ transplants, among others.
AU2009219154A1 (en) 2008-02-29 2009-09-03 Cylene Pharmaceuticals, Inc. Protein kinase modulators
EA019223B1 (en) 2008-03-04 2014-02-28 Натко Фарма Лимитед Crystal form of phenylamino pyrimidine derivatives
US20090227575A1 (en) 2008-03-04 2009-09-10 Wyeth 7H-PYRROLO[2,3-H]QUINAZOLINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESIS
EP2262806A1 (en) 2008-03-06 2010-12-22 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
UY31700A (en) 2008-03-13 2009-11-10 Boehringer Ingelheim Int TIAZOLIL-DIHIDRO-INDAZOLES
JP5547099B2 (en) 2008-03-14 2014-07-09 インテリカイン， エルエルシー Kinase inhibitors and methods of use
WO2009114874A2 (en) 2008-03-14 2009-09-17 Intellikine, Inc. Benzothiazole kinase inhibitors and methods of use
EP2966076A1 (en) 2008-03-19 2016-01-13 ChemBridge Corporation Novel tyrosine kinase inhibitors
CN101977912A (en) 2008-03-19 2011-02-16 Osi医药有限公司 Salt forms of mTOR inhibitors
US8268834B2 (en) 2008-03-19 2012-09-18 Novartis Ag Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
JP2011515462A (en) 2008-03-27 2011-05-19 アウククランド ウニセルビセス リミテッド Substituted pyrimidines and triazines and their use in cancer therapy
CN102333779B (en) 2008-03-31 2015-12-09 吉宁特有限公司 Benzopyran and Benzoxepin* PI3K Inhibitor Compounds and Methods of Use
US20090258907A1 (en) 2008-04-09 2009-10-15 Abbott Laboratories Compounds useful as inhibitors of rock kinases
WO2009129259A2 (en) 2008-04-16 2009-10-22 Takeda Pharmaceutical Company Limited Polymorphs of 5-(3-(ethylsulfonyl)phenyl)-3,8-dimethyl-n-(1-methylpiperidin-4-yl)-9h-pyrido[2,3-b]indole-7-carboxamide and methods of use therefor
JP2011518168A (en) 2008-04-16 2011-06-23 バーテックス ファーマシューティカルズ インコーポレイテッド Inhibitors of phosphatidylinositol 3-kinase
EP2346508B1 (en) 2008-09-26 2016-08-24 Intellikine, LLC Heterocyclic kinase inhibitors
JP5819195B2 (en) 2008-10-16 2015-11-18 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Fusion ring heteroaryl kinase inhibitors
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
WO2010059593A1 (en) 2008-11-18 2010-05-27 Intellikine, Inc. Methods and compositions for treatment of ophthalmic conditions
AR077267A1 (en) 2009-06-25 2011-08-17 Amgen Inc SELECTED INHIBITING NITROGEN DERIVATIVES OF PI3K, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USE OF THE SAME IN THE TREATMENT OF INFLAMMATORY AND / OR AUTOIMMUNE DISEASES.
HRP20171537T1 (en) * 2009-11-05 2017-12-15 Rhizen Pharmaceuticals S.A. Novel benzopyran kinase modulators
WO2011153553A2 (en) 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition
BR112013027774B1 (en) 2011-05-04 2020-11-17 Rhizen Pharmaceuticals S.A. pharmaceutical compound and composition
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
ES2647416T3 (en) * 2012-07-04 2017-12-21 Rhizen Pharmaceuticals S.A. Selective delta PI3K inhibitors
WO2014060431A1 (en) 2012-10-16 2014-04-24 Almirall, S.A. Pyrrolotriazinone derivatives as pi3k inhibitors
US20140120060A1 (en) 2012-11-01 2014-05-01 Infinity Pharmaceuticals, Inc. Treatment of rheumatoid arthritis and asthma using pi3 kinase inhibitors
HRP20181367T4 (en) 2012-11-01 2021-11-26 Infinity Pharmaceuticals, Inc. TREATMENT OF CANCER USING PI3 KINASE ISOFORM MODULATORS
KR20150079745A (en) * 2012-11-08 2015-07-08 리젠 파마슈티컬스 소시에떼 아노님 Pharmaceutical compositions containing a pde4 inhibitor and a pi3 delta or dual pi3 delta-gamma kinase inhibitor

Also Published As

Publication number Publication date
US11020399B2 (en) 2021-06-01
EP2705029B1 (en) 2018-10-24
WO2012151525A1 (en) 2012-11-08
HUE042322T2 (en) 2019-06-28
US20120289496A1 (en) 2012-11-15
KR101992311B1 (en) 2019-09-27
US9775841B2 (en) 2017-10-03
ZA201307964B (en) 2015-01-28
SG194718A1 (en) 2013-12-30
DK2705029T3 (en) 2019-02-18
JP2017119708A (en) 2017-07-06
LT2705029T (en) 2019-02-11
KR20140058431A (en) 2014-05-14
CA2833935A1 (en) 2012-11-08
CO6852069A2 (en) 2014-01-30
AP2013007225A0 (en) 2013-11-30
MY168757A (en) 2018-12-04
MX365160B (en) 2019-05-24
US20180110783A1 (en) 2018-04-26
AU2012250576B2 (en) 2017-04-27
CN103702989B (en) 2017-07-07
US10220035B2 (en) 2019-03-05
US20190105324A9 (en) 2019-04-11
CN103702989A (en) 2014-04-02
CA2833935C (en) 2020-09-15
PL2705029T4 (en) 2019-09-30
SMT201900056T1 (en) 2019-02-28
NZ616834A (en) 2015-10-30
RS58326B1 (en) 2019-03-29
US10322130B2 (en) 2019-06-18
JP2014513137A (en) 2014-05-29
PL2705029T3 (en) 2019-04-30
EA024842B1 (en) 2016-10-31
US20150320752A1 (en) 2015-11-12
CN107337659A (en) 2017-11-10
AP4075A (en) 2017-03-23
EA024842B9 (en) 2017-08-31
SI2705029T1 (en) 2019-03-29
ES2710874T3 (en) 2019-04-29
PH12013502240A1 (en) 2014-01-06
CY1121170T1 (en) 2020-05-29
PT2705029T (en) 2019-02-01
BR112013027774A2 (en) 2017-11-07
BR112013027774B1 (en) 2020-11-17
AU2012250576A1 (en) 2013-11-07
EA201391416A1 (en) 2014-04-30
MX2013012896A (en) 2014-05-21
JP6118314B2 (en) 2017-04-19
WO2012151525A9 (en) 2012-12-13
US20210401840A1 (en) 2021-12-30
EP2705029A1 (en) 2014-03-12
US20190282581A1 (en) 2019-09-19
HRP20190128T1 (en) 2019-03-08
PH12013502240B1 (en) 2018-06-27

Similar Documents

Publication Publication Date Title
CL2013003160A1 (en) Compounds derived from 4h-chromen-4-one modulators of the protein kinase pi3k; intermediary compounds; pharmaceutical composition that includes them; and useful in the treatment of cancer, anti-inflammatory agents, immunosuppressants, steroids, analgesics, leukemia, among others.
CY1125358T1 (en) COMBINATION THERAPY INCLUDING AN MDM2 INHIBITOR AND ONE OR MORE ADDITIONAL PHARMACEUTICALLY ACTIVE AGENTS FOR THE TREATMENT OF CANCER
CR20170116A (en) COMPOUNDS THAT INHIBIT THE PROTEIN MCL-1
CY1120866T1 (en) DNA-PK INHIBITORS
CL2018001685A1 (en) Heterocyclic compounds as immuno modulators.
MX386935B (en) PRODRUGS OF FUMARATES AND THEIR USE IN THE TREATMENT OF DIFFERENT DISEASES.
CL2015002767A1 (en) Therapeutic compounds and compositions
CR20150316A (en) COMPOUNDS AND THEIR EMPLOYMENT METHODS
MX2017015470A (en) Tyrosine kinase inhibitors.
UY35590A (en) NEW COMPOUNDS FOR CANCER TREATMENT
MX2015015738A (en) DERIVATIVES OF BIPIRAZOL AS INHIBITORS OF JANUS CINASA (JAK).
UY35898A (en) ? SYK INHIBITING COMPOUNDS AND COMPOSITIONS THAT UNDERSTAND THEM ?.
MX2020010412A (en) Inhibitors of bruton's tyrosine kinase.
CL2011000589A1 (en) Compounds derived from pyrrolidin-2-carboxamide, p53-mdm2 interaction inhibitors; pharmaceutical composition that includes them; and its use in the preparation of useful medicines for the treatment of cancer.
CL2012001821A1 (en) Compounds derived from 5-alkynyl-pyrimidines, kinase inhibitors; pharmaceutical compositions containing them; and its use for the treatment and / or prevention of cancer, infections, inflammatory and autoimmune diseases.
MX2017013886A (en) Azabenzimidazoles and their use as ampa receptor modulators.
MX2019012847A (en) C5-anilinoquinazoline compounds and their use in treating cancer.
MX2018005725A (en) Dihydroimidazopyrazinone derivatives useful in the treatment of cancer.
CR20140071A (en) NEW 4-PIPERIDINYL COMPOUNDS FOR USE AS TANKIRASA INHIBITORS
NI201500096A (en) CHEMICAL COMPOUNDS
CY1122313T1 (en) ORBEPITANTE FOR THE TREATMENT OF CHRONIC IGNITION
UY36875A (en) BROMODOMINIUM INHIBITING COMPOSITIONS FOR THE TREATMENT OF VARIOUS DISEASES
CO6341625A2 (en) DERIVATIVES OF INDOL AS ANTI-CANCER AGENTS
CY1122357T1 (en) ANTI-CANCER COMBINATION INCLUDING CABAZITAXEL AND cisplatin
CL2011002946A1 (en) Compounds derived from thiazolthiadiazole aminopyrazole, protein kinase inhibitors c-met; pharmaceutical composition that comprises them and their use in the treatment of different types of cancer.